Icon PLC

The CRO services market was valued at USD 111.8 billion in 2024 and is expected to reach USD 166 billion by 2029, driven by increased outsourcing, specialized demand, and the rise of generic drugs. Advanced treatments and adaptive trial designs are enhancing clinical trials, while chronic diseases and drug discovery are boosting market growth.

Phase III dominated the omics-based clinical trials market in 2024, with phase I expected to grow fastest. Interventional studies led, with observational studies projected to grow fastest. Oncology dominated, with inflammation/autoimmune expected to grow fastest. North America led, with Asia Pacific and China showing significant growth. Key companies include Parexel, Thermo Fisher Scientific, and Pfizer. Recent developments include Macrogen and PacBio's lab opening in Singapore and Eli Lilly's collaboration with 5 Prime Sciences.

Global Immuno-Oncology Clinical Trials Market report analyzes current status, future trends, and growth, covering major players like ICON PLC, IQVIA Holdings Inc., Covance, BioNTech, and others. It provides historical, current, and forecast market size, segmentation, and regional analysis. Key factors influencing market dynamics, including drivers, restraints, and projections, are detailed. The report also offers insights into market shares, strategies, and emerging niche segments.

Kuwait in vivo CRO market generated USD 5.8 million in 2023, expected to reach USD 9.8 million by 2030 with a CAGR of 7.7%. Small molecule was the largest segment in 2023, while Large Molecule is the fastest growing. Kuwait accounted for 0.1% of the global market in 2023, with the U.S. leading globally and South Africa leading in the Middle East & Africa by 2030.

The South Korea in vivo CRO market generated USD 36.1 million in 2023, projected to reach USD 65.9 million by 2030, growing at a CAGR of 9%. Small molecule was the largest segment in 2023, while Large Molecule is expected to grow fastest. South Korea accounted for 0.8% of the global market in 2023, with the U.S. leading globally and Japan leading in Asia Pacific by 2030. India is the fastest-growing regional market in Asia Pacific, projected to reach USD 122.7 million by 2030.

France in vivo CRO market generated USD 230.2 million in 2023, expected to reach USD 399.6 million by 2030 with an 8.2% CAGR. Small molecule led in 2023, while Large Molecule is fastest growing. Factors driving growth include increasing preclinical studies, outsourcing, skilled professionals, and R&D investments.

The Functional Service Providers (FSP) Market was valued at USD 14.68 billion in 2023 and is projected to reach USD 30.70 billion by 2032, growing at a CAGR of 8.56%. The market's expansion is driven by the complexity of clinical trials, increased R&D investments, and the need for specialized services. Pharmaceutical and biotechnology companies are increasingly outsourcing to optimize trial efficiency and reduce costs. FSPs leverage technologies like AI and big data analytics to enhance trial design and execution. The market is segmented by type, stage, and application, with North America leading and Asia Pacific expected to grow the fastest.

Offshoring clinical trials market is rapidly expanding due to cost savings, quicker patient recruitment, and access to diverse populations, particularly in Asia-Pacific, Latin America, and Eastern Europe. Key factors driving growth include regulatory harmonisation, digital health tools, and remote monitoring. The market is projected to reach 12.4 billion USD by 2033, growing at a CAGR of 9.1%.

Global pharmaceutical CRO market to reach USD 91.20 billion by 2034, driven by chronic disease burden and R&D demand. Asia Pacific leads with 47% share in 2023, while North America shows fastest growth. Clinical segment dominates with 76% share, and small molecule segment leads in 2023. Oncology is the largest therapeutic area, with immunology expected to grow significantly. Technological advancements and AI impact efficiency and cost in clinical trials.